Abivax (ABVX) and Nektar Therapeutics (NKTR) are emerging players in the biotech sector, both currently in clinical stages without approved drugs, yet with promising therapies that could reshape their futures. Abivax’s lead candidate, obefazimod, is undergoing phase 3 trials for ulcerative colitis, with results expected in Q2 2026, while Nektar’s rezpegaldesleukin shows strong potential in treating atopic dermatitis, supported by favorable phase 2b trial results.

The performance of these stocks could hinge on their clinical outcomes and potential buyout interest. Abivax has seen a staggering 1,900% increase over the past year, fueled by positive trial results and acquisition rumors, while Nektar’s recent capital raise has bolstered its liquidity, positioning it well for future growth. Analysts are optimistic, with price targets for Nektar suggesting significant upside.

Investors should closely monitor these companies as they navigate their clinical trials and market positioning, especially with possible acquisition scenarios on the horizon. For a deeper dive into their potential, I recommend checking out the full article.

Source: fool.com